• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在中国批准碳青霉烯类药物之前,耐碳青霉烯类大肠埃希菌出现高水平的头孢地尔耐药性:来自中国 CRE 网络的报告。

Occurrence of High Levels of Cefiderocol Resistance in Carbapenem-Resistant Escherichia coli before Its Approval in China: a Report from China CRE-Network.

机构信息

Department of Clinical Laboratory, Peking University People's Hospital, Beijing, China.

Department of Clinical Laboratory, The Third Hospital of Mianyang, Sichuan, China.

出版信息

Microbiol Spectr. 2022 Jun 29;10(3):e0267021. doi: 10.1128/spectrum.02670-21. Epub 2022 Apr 28.

DOI:10.1128/spectrum.02670-21
PMID:35481835
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9241927/
Abstract

Cefiderocol has been approved in the United States and Europe but not in China. We aim to evaluate carbapenem-resistant (CRE) susceptibility to cefiderocol to provide baseline data and investigate the resistance mechanism. From 2018 to 2019, 1,158 CRE isolates were collected from 23 provinces and municipalities across China. The MICs of antimicrobials were determined via the agar dilution and broth microdilution methods. Whole-genome sequencing was performed for 26 cefiderocol-resistant Escherichia coli isolates to investigate the resistance mechanism. Clone transformations were used to explore the function of , , and in resistance. Among the 21 antimicrobials tested, aztreonam-avibactam had the highest antibacterial activity (98.3%), followed by cefiderocol (97.3%) and colistin (95.3%). A total of 26 E. coli isolates harboring New Delhi metallo-beta-lactamase 5 (NDM-5) showed high levels of cefiderocol resistance, of which sequence type 167 (ST167) accounted for 76.9% (20/26). We found 4 amino-acid insertions (YRIN/YRIK) at position 333 of penicillin-binding protein 3 (PBP3) in the 26 E. coli isolates, and 22 isolates had a siderophore receptor premature stop codon. After obtaining the wild-type supplementation, the MIC of the transformants decreased by 8 to 16 times in two cefiderocol-resistant isolates. A cefiderocol-susceptible isolate harboring NDM-5 has an MIC increased from 1 μg/mL to 64 μg/mL after deletion, and the MIC decreased from 64 μg/mL to 0.5 μg/mL after deletion. The MIC of the E. coli DH5α, from which the mutant was obtained, increased from 0.064 μg/mL to 0.25 μg/mL. Cefiderocol showed activity against most CRE in China. The resistance of ST167 E. coli to cefiderocol is a combination of the premature stop codon of , mutation, and existence. Cefiderocol, a new siderophore cephalosporin, has been approved in the United States and Europe but not in China. At present, there are almost no antimicrobial susceptibility evaluation data on cefiderocol in China. We evaluated the susceptibility of 1,158 strains of carbapenem-resistant to cefiderocol and other antibiotics. We found that a high proportion of Escherichia coli showed high-level resistance to cefiderocol. Whole-genome sequencing (WGS) and molecular cloning experiments confirmed that the synergistic effect of the gene premature stop codon, existence, and the mutation is associated with high levels of cefiderocol resistance.

摘要

头孢地尔在美欧获得批准,但尚未在国内获得批准。本研究旨在评估头孢地尔对碳青霉烯类耐药肠杆菌(CRE)的敏感性,为临床提供基线数据并探讨耐药机制。2018 年至 2019 年,我们从中国 23 个省、直辖市收集了 1158 株 CRE 分离株。采用琼脂稀释法和肉汤微量稀释法测定抗菌药物的 MIC。对 26 株头孢地尔耐药大肠埃希菌进行全基因组测序,以研究耐药机制。通过克隆转化来探讨 、 和 在耐药中的作用。在所测试的 21 种抗生素中,氨曲南-阿维巴坦(Aztreonam-avibactam)具有最高的抗菌活性(98.3%),其次是头孢地尔(97.3%)和黏菌素(95.3%)。26 株携带新德里金属β-内酰胺酶 5(NDM-5)的大肠埃希菌表现出高水平的头孢地尔耐药性,其中序列型 167(ST167)占 76.9%(20/26)。我们在 26 株大肠埃希菌中发现 4 个氨基酸插入(YRIN/YRIK)在青霉素结合蛋白 3(PBP3)的 333 位,22 株菌存在铁载体受体 提前终止密码子。在获得野生型 后,两株头孢地尔耐药株的转化子 MIC 降低了 8 至 16 倍。携带 NDM-5 的头孢地尔敏感株 缺失后 MIC 从 1μg/ml 增加到 64μg/ml,而 缺失后 MIC 从 64μg/ml 降低到 0.5μg/ml。从获得 突变体的大肠埃希菌 DH5α,其 MIC 从 0.064μg/ml 增加到 0.25μg/ml。头孢地尔对中国大部分 CRE 具有活性。ST167 大肠埃希菌对头孢地尔的耐药性是 提前终止密码子、 突变和 存在的组合。头孢地尔是一种新型的铁载体头孢菌素,已在美国和欧洲获得批准,但尚未在中国获得批准。目前,中国几乎没有头孢地尔药敏评价数据。我们评估了 1158 株耐碳青霉烯类肠杆菌对头孢地尔和其他抗生素的敏感性。我们发现,相当比例的大肠埃希菌对头孢地尔表现出高水平的耐药性。全基因组测序(WGS)和分子克隆实验证实, 基因提前终止密码子、 存在和 突变的协同作用与头孢地尔的高水平耐药有关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66dd/9241927/d42f5d20a55c/spectrum.02670-21-f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66dd/9241927/c628eb2fd486/spectrum.02670-21-f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66dd/9241927/d42f5d20a55c/spectrum.02670-21-f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66dd/9241927/c628eb2fd486/spectrum.02670-21-f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66dd/9241927/d42f5d20a55c/spectrum.02670-21-f002.jpg

相似文献

1
Occurrence of High Levels of Cefiderocol Resistance in Carbapenem-Resistant Escherichia coli before Its Approval in China: a Report from China CRE-Network.在中国批准碳青霉烯类药物之前,耐碳青霉烯类大肠埃希菌出现高水平的头孢地尔耐药性:来自中国 CRE 网络的报告。
Microbiol Spectr. 2022 Jun 29;10(3):e0267021. doi: 10.1128/spectrum.02670-21. Epub 2022 Apr 28.
2
Emergence of High-Level Cefiderocol Resistance in Carbapenem-Resistant Klebsiella pneumoniae from Bloodstream Infections in Patients with Hematologic Malignancies in China.中国血液系统恶性肿瘤患者血流感染碳青霉烯类耐药肺炎克雷伯菌中高水平头孢地尔耐药的出现。
Microbiol Spectr. 2022 Apr 27;10(2):e0008422. doi: 10.1128/spectrum.00084-22. Epub 2022 Mar 24.
3
When the Trojan horse is unable to reach inside the city: investigation of the mechanism of resistance behind the first reported cefiderocol-resistant in Canada.当木马无法进入城内时:首次在加拿大报道的头孢地尔耐药的耐药机制调查。
Microbiol Spectr. 2024 May 2;12(5):e0322323. doi: 10.1128/spectrum.03223-23. Epub 2024 Mar 25.
4
An NDM-Producing Clinical Isolate Exhibiting Resistance to Cefiderocol and the Combination of Ceftazidime-Avibactam and Aztreonam: Another Step Toward Pan-β-Lactam Resistance.一株产NDM的临床分离株对头孢地尔、头孢他啶-阿维巴坦合剂及氨曲南耐药:迈向泛β-内酰胺耐药的又一步。
Open Forum Infect Dis. 2023 May 17;10(7):ofad276. doi: 10.1093/ofid/ofad276. eCollection 2023 Jul.
5
NDM-35-Producing ST167 Highly Resistant to β-Lactams Including Cefiderocol.产 NDM-35 的 ST167 对包括头孢地尔在内的β-内酰胺类高度耐药。
Antimicrob Agents Chemother. 2022 Aug 16;66(8):e0031122. doi: 10.1128/aac.00311-22. Epub 2022 Jul 11.
6
In vitro antibacterial activity of cefiderocol against recent multidrug-resistant carbapenem-nonsusceptible Enterobacterales isolates.头孢地尔罗对近期多重耐药碳青霉烯类药物不敏感的肠杆菌科分离株的体外抗菌活性。
Diagn Microbiol Infect Dis. 2022 May;103(1):115651. doi: 10.1016/j.diagmicrobio.2022.115651. Epub 2022 Jan 31.
7
Progressive Development of Cefiderocol Resistance in Escherichia coli During Therapy is Associated With an Increase in blaNDM-5 Copy Number and Gene Expression.治疗期间大肠杆菌中头孢地尔耐药性的逐步发展与blaNDM - 5拷贝数和基因表达的增加有关。
Clin Infect Dis. 2022 Aug 24;75(1):47-54. doi: 10.1093/cid/ciab888.
8
Evolution of Cefiderocol Resistance in an NDM-Producing Klebsiella pneumoniae Due to Functional Loss of CirA.产新德里金属β-内酰胺酶(NDM)肺炎克雷伯菌因 CirA 功能丧失导致头孢地尔耐药性的演变。
Microbiol Spectr. 2021 Dec 22;9(3):e0177921. doi: 10.1128/Spectrum.01779-21. Epub 2021 Nov 10.
9
Activity of aztreonam/avibactam against metallo-β-lactamase-producing Enterobacterales from the UK: Impact of penicillin-binding protein-3 inserts and CMY-42 β-lactamase in Escherichia coli.替加环素/阿维巴坦对英国产金属β-内酰胺酶肠杆菌科的活性:青霉素结合蛋白 3 插入物和大肠埃希菌中的 CMY-42β-内酰胺酶的影响。
Int J Antimicrob Agents. 2023 May;61(5):106776. doi: 10.1016/j.ijantimicag.2023.106776. Epub 2023 Mar 8.
10
Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance Program.头孢地尔在 2020 年 SENTRY 抗菌监测计划中对美国和欧洲革兰氏阴性临床分离株的活性。
Microbiol Spectr. 2022 Apr 27;10(2):e0271221. doi: 10.1128/spectrum.02712-21. Epub 2022 Mar 9.

引用本文的文献

1
Exploring mutational possibilities of KPC variants to reach high level resistance to cefiderocol.探索KPC变体达到对头孢地尔高水平耐药的突变可能性。
Sci Rep. 2025 Aug 25;15(1):31312. doi: 10.1038/s41598-025-17044-8.
2
Metabolic reprogramming enhances the susceptibility of multidrug- and carbapenem-resistant bacteria to antibiotics.代谢重编程增强了多重耐药菌和碳青霉烯耐药菌对抗生素的敏感性。
Nat Microbiol. 2025 Aug 11. doi: 10.1038/s41564-025-02083-8.
3
Cefiderocol "under siege"? Understanding the rise of NDM-mediated resistance to novel agents.

本文引用的文献

1
New Delhi Metallo-Beta-Lactamase Facilitates the Emergence of Cefiderocol Resistance in Enterobacter cloacae.新德里金属-β-内酰胺酶促进阴沟肠杆菌对头孢地尔罗耐药的产生。
Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0201121. doi: 10.1128/AAC.02011-21. Epub 2021 Dec 6.
2
Progressive Development of Cefiderocol Resistance in Escherichia coli During Therapy is Associated With an Increase in blaNDM-5 Copy Number and Gene Expression.治疗期间大肠杆菌中头孢地尔耐药性的逐步发展与blaNDM - 5拷贝数和基因表达的增加有关。
Clin Infect Dis. 2022 Aug 24;75(1):47-54. doi: 10.1093/cid/ciab888.
3
Overview of Changes to the Clinical and Laboratory Standards Institute M100, 31st Edition.
头孢地尔“被围攻”?解读NDM介导的对新型药物耐药性的上升。
Chem Sci. 2025 Jun 3. doi: 10.1039/d5sc02122g.
4
Combined resistance mechanisms leading to high-level of cefiderocol resistance among NDM-like producing E. coli ST167 clinical isolates.导致产NDM样的大肠杆菌ST167临床分离株对头孢地尔产生高水平耐药的联合耐药机制。
Eur J Clin Microbiol Infect Dis. 2025 May 27. doi: 10.1007/s10096-025-05166-w.
5
Prevalence of New Delhi Metallo-β-lactamase (bla) gene in a selected population of drug-resistant clinical isolates.新德里金属β-内酰胺酶(bla)基因在特定耐药临床分离株群体中的流行情况。
Mol Biol Rep. 2025 Apr 15;52(1):388. doi: 10.1007/s11033-025-10446-x.
6
Antimicrobial and anti-inflammatory effects of antimicrobial peptide Lf-KR against carbapenem-resistant Escherichia coli.抗菌肽Lf-KR对耐碳青霉烯类大肠杆菌的抗菌及抗炎作用
BMC Microbiol. 2025 Mar 31;25(1):183. doi: 10.1186/s12866-025-03906-8.
7
Global molecular epidemiology of the incomplete CirA protein related to cefiderocol resistance in : a genome-based study.基于基因组的研究:与头孢地尔耐药性相关的不完整CirA蛋白的全球分子流行病学
Microbiol Spectr. 2025 May 6;13(5):e0141024. doi: 10.1128/spectrum.01410-24. Epub 2025 Mar 19.
8
Pharmacokinetic, Pharmacokinetic/Pharmacodynamic, and Safety Investigations of Cefiderocol in Chinese Healthy Subjects.头孢地尔在中国健康受试者中的药代动力学、药代动力学/药效学及安全性研究。
Adv Ther. 2025 May;42(5):2285-2297. doi: 10.1007/s12325-025-03147-1. Epub 2025 Mar 13.
9
Post-market safety profile of cefiderocol: a real-world pharmacovigilance exploratory analysis based on U.S. FDA adverse event reporting system (FAERS).头孢地尔的上市后安全性概况:基于美国食品药品监督管理局不良事件报告系统(FAERS)的真实世界药物警戒探索性分析
BMC Pharmacol Toxicol. 2025 Mar 11;26(1):58. doi: 10.1186/s40360-025-00894-3.
10
In vitro activity and resistance mechanisms of novel antimicrobial agents against metallo-β-lactamase producers.新型抗菌剂对金属β-内酰胺酶产生菌的体外活性及耐药机制
Eur J Clin Microbiol Infect Dis. 2025 May;44(5):1041-1068. doi: 10.1007/s10096-025-05080-1. Epub 2025 Mar 10.
临床和实验室标准协会 M100,31 版更改概述。
J Clin Microbiol. 2021 Nov 18;59(12):e0021321. doi: 10.1128/JCM.00213-21. Epub 2021 Sep 22.
4
Rapid Development of Cefiderocol Resistance in Carbapenem-resistant Enterobacter cloacae During Therapy Is Associated With Heterogeneous Mutations in the Catecholate Siderophore Receptor cirA.在治疗过程中,产碳青霉烯酶阴沟肠杆菌对头孢他啶的耐药性迅速发展与儿茶酚载体铁载体受体 cirA 中的异质性突变有关。
Clin Infect Dis. 2022 Mar 9;74(5):905-908. doi: 10.1093/cid/ciab511.
5
Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections.头孢地尔罗:一种新型的用于治疗多重耐药革兰氏阴性菌感染的铁载体头孢菌素。
J Antimicrob Chemother. 2021 May 12;76(6):1379-1391. doi: 10.1093/jac/dkab015.
6
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.头孢地尔罗或最佳现有治疗方案治疗碳青霉烯类耐药革兰氏阴性菌引起的严重感染的疗效和安全性(CREDIBLE-CR):一项随机、开放标签、多中心、以病原体为重点、描述性的 3 期临床试验。
Lancet Infect Dis. 2021 Feb;21(2):226-240. doi: 10.1016/S1473-3099(20)30796-9. Epub 2020 Oct 12.
7
Changing Epidemiology and Decreased Mortality Associated With Carbapenem-resistant Gram-negative Bacteria, 2000-2017.2000-2017 年耐碳青霉烯类革兰阴性菌的流行情况变化与死亡率降低相关。
Clin Infect Dis. 2021 Dec 6;73(11):e4521-e4530. doi: 10.1093/cid/ciaa1464.
8
Cefiderocol Resistance in Acinetobacter baumannii: Roles of β-Lactamases, Siderophore Receptors, and Penicillin Binding Protein 3.鲍曼不动杆菌中头孢地尔罗耐药性:β-内酰胺酶、铁载体受体和青霉素结合蛋白 3 的作用。
Antimicrob Agents Chemother. 2020 Oct 20;64(11). doi: 10.1128/AAC.01221-20.
9
Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014).全球监测项目(SIDERO-WT-2014)中临床分离株对头孢他啶的亲和力降低机制(铁载体头孢菌素)。
J Glob Antimicrob Resist. 2020 Sep;22:738-741. doi: 10.1016/j.jgar.2020.07.009. Epub 2020 Jul 21.
10
Antimicrobial Resistance in ESKAPE Pathogens.ESKAPE 病原体中的抗微生物药物耐药性。
Clin Microbiol Rev. 2020 May 13;33(3). doi: 10.1128/CMR.00181-19. Print 2020 Jun 17.